Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study

This was an 8-week, multicenter, randomized, single-blind, active-controlled trial conducted at a psychiatric hospital (Beijing Anding Hospital) and a general hospital (Beijing Chaoyang Hospital) between April 2013 and September 2017. The study protocol was approved by the ethical review board at each study center. The study was carried out according to the Declaration of Helsinki and the guidelines for good clinical practice. The trial was registered (Clinical Trials. gov #NCT01824433), prior to the study. Written informed consent was obtained from all participants before the commencement of any study procedures. Patients were informed that they were free to withdraw from the trial at any time.

Outpatient participants had to be ≥50 years old and to meet the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria for MDD, as determined by the Mini International Neuropsychiatric Interview (MINI). Menopausal status and menopausal age were self-reported. Menopause was defined as at least 1 year without menses. MDD could be newly-diagnosed with depressive episodes within 1 year or recurrent with at least 5 years from the last depressive episodes. Patients were required to have a 24-item Hamilton Depression Rating Scale (HAMD-24) total score ≥ 20, and HAMD item 1 (depressed mood) score ≥ 2 at screening and baseline. The exclusion criteria were: 1) current diagnosis of DSM-IV-TR axis I psychiatric illness such as schizophrenia, bipolar disorder, mental retardation, brain organic mental disorders, mental disorders due to a general medical condition, and any substance abuse disorder; 2) clinically significant medical diseases, including any cardiovascular, hepatic, renal, respiratory, hematologic, endocrinological, and neurologic diseases; 3) clozapine use up to 3 months before screening; 4) history of lacked efficacy of venlafaxine or fluoxetine; 5) not receiving hormonal replacement therapy; 6) treatment with electroconvulsive therapy (ECT) within 3 months prior to screening.

Patients meeting the eligibility criteria at baseline were randomly allocated to fluoxetine or venlafaxine at a 1:1 ratio using a computer-generated list of random numbers. In order to ensure allocation concealment, sequentially numbered opaque sealed envelopes were used. Individuals were randomized to groups by a researcher not connected to the study team. The raters who performed the evaluations were blinded to individual treatment assignments. All other researchers and the patients were unblinded to treatment group assignment.

The doses of venlafaxine and fluoxetine were tailored based on clinical considerations determined by the investigators at each site. The patients randomized to oral venlafaxine were initiated at a dose of 75 mg/d at the investigators’ considerations. Based on response and tolerability, the dose could be titrated upward to 150 mg/d at a 2-week interval, while the maximal dose was 225 mg/d. The patients randomized to oral fluoxetine were initiated at an initial dose of 20 mg/d, and the dose could be titrated upward by 10-mg increments at 2-week intervals according to investigators’ judgment to a maximum daily dose of 60 mg. The total study period was 8 weeks. The patients were examined at baseline and at weeks 1, 2, 4, 6, and 8.

The participants were not allowed to take any treatment that may affect the study drug’s efficacy, such as other psychotropic drugs, ECT, and psychotherapy. Benzodiazepines (preferred lorazepam) were prohibited 8 h before the psychiatric evaluations. Trihexyphenidyl could be used for extrapyramidal symptoms but not for prophylaxis, to a maximal dose of 12 mg/d during the study.

The primary efficacy endpoint was the mean change in the HAMD-24 scores from baseline to week 8. The secondary efficacy endpoints were: 1) the mean change in the anxiety/somatization factor scores (sum of items 10–13, 15, and 17); 2) the proportion of Clinical Global Impressions-Improvement (CGI-I) score of 1 or 2 (very much or much improved) at week 8.

The HAMD-24 is a questionnaire used to provide an indication of depression in adults and to evaluate recovery and remission [15, 16]. The CGI-I scale is a investigators’ assessment of how much the illness improved or worsened in relation to baseline [17].

All patients underwent a complete physical examination at the beginning of the trial and at each subsequent visit. Safety was assessed based on the adverse events (AEs) recorded by the investigators. Electrocardiogram (ECG) recordings were performed at baseline and at 8 weeks. Blood pressure and heart rate were assessed at each study visit.

The sample-size calculation showed that using a power of 90%, a total of 160 patients (80 in each treatment group) were required to demonstrate the superiority of venlafaxine to fluoxetine, with α set at 5%. Assuming a drop-out rate of 20%, enrolling 200 patients (100 in each group) was necessary. This was based on a superiority comparison of the treatment groups in HAMD-24 total score using a two-sided 95% confidence interval against a margin of 1.8 points, a standard deviation of 3.5 [18], and an expected true mean difference of 0 points between treatments.

Efficacy was analyzed using the full analysis set (FAS) following the modified intention-to-treat (mITT) principle, which included all randomized women who met the study criteria and took at least one dose of study drug and who had one or more post-baseline HAMD-24 evaluations. Per-protocol (PP) analysis refers to inclusion in the analysis of only those patients who strictly adhered to the protocol. Safety analyses were based on the safety set (SS), comprising all randomized patients who took at least one dose of study medication.

Figure 1 presents the patient flowchart. A total of 189 women were screened: five participants failed screening, and 184 women were randomized. The clinical and socio-demographic characteristics of the participants are presented in Table 1. There were no statistically significant differences between the two groups. Among them, 130 (63 on venlafaxine and 67 on fluoxetine) completed the 8-week study period; 26/90 (28.9%) participants in the venlafaxine group and 28/94 (29.8%) in the fluoxetine group dropped out from the study (P = 0.894). A total of 54 patients were discontinued from the study. The main reasons for discontinuation were participant decision (n = 11), poor adherence (n = 14), intolerable side effects (n = 11), loss to follow-up (n = 9), lack of efficacy (n = 5) and other reasons (n = 4). The mean daily doses for venlafaxine and fluoxetine at week 8 were 141.96 (55.3) mg/day and 38.96 (12.59) mg/day, respectively.

The MMRM model revealed differences between the two groups on the total anxiety/somatization factor scores (F_(1,137) = 14.5, P < 0.01) (Table 2 and Fig. 3). Venlafaxine group decreased significantly compared with fluoxetine group in anxiety/somatization factor scores (LSMD [95% CI]: − 2.33 [− 2.25, − 0.19]). The anxiety/somatization factor scores were reduced over the course of treatment for each group (F_(4,133) = 58.4, P < 0.01).

At 8 weeks, the proportion of responders on CGI-I was 68.9% in the venlafaxine group and 48.5% in the fluoxetine group (P = 0.019) (Fig. 4).

Safety analyses were performed in 89 subjects on venlafaxine and 93 on fluoxetine. Twenty-four subjects in the venlafaxine group (27.0%; 31 events) and 30 in the fluoxetine group (32.3%; 44 events) reported treatment-emergent adverse events (TEAEs) (P = 0.435). Study drug-related TEAEs were reported by 16 subjects in the venlafaxine group (18.0%, 20 events) and 25 in the fluoxetine group (26.9%, 36 events)(P = 0.151). Three subjects in the venlafaxine group (3.4%) and eight in the fluoxetine group (8.6%) discontinued treatment because of TEAEs (P = 0.139). All TEAEs were mild or moderate in severity.

The most common drug-related TEAEs reported by the patients in the venlafaxine group were nausea (15.7%), somnolence (6.7%), and dizziness (5.6%). The most common TEAEs in the fluoxetine group were nausea (11.8%), dry mouth (7.5%), dizziness (6.5%), and headache (5.4%). The venlafaxine group exhibited a significantly higher incidence of leukopenia, constipation, and difficulty urinating. The fluoxetine group had a higher incidence of increased intraocular pressure (Table 3). No SAE was reported. One participant reported a patellar fracture, and one participant in the fluoxetine group reported cervical spondylosis (not study drug-related).

Previous studies comparing SNRIs and SSRIs in the treatment of postmenopausal MDD have several limitations [8‐11, 19, 20]. Therefore, the aim of this study was to compare the efficacy and safety of venlafaxine vs. fluoxetine in the treatment of postmenopausal MDD. The results suggested that venlafaxine was well tolerated, leading to greater improvement than fluoxetine in the treatment of postmenopausal MDD. The safety profile was comparable between the two groups.

This is the first multicenter, randomized, controlled trial that evaluated the efficacy of fluoxetine vs. venlafaxine in women with postmenopausal MDD. The symptoms of depression significantly improved in both groups; however, venlafaxine was superior to fluoxetine in controlling depression symptoms. Our results showed that menopause affected SSRI’s antidepressant effect, which is consistent with other studies comparing the effect of SNRIs and SSRIs in menopausal depression [11]. SNRIs may have a consistent antidepressant effect in women across different ages and menopausal staging. In their study on sleep-related issues, Davari-Tanha et al suggested that venlafaxine is more efficacious than citalopram in the treatment of depression in postmenopausal women [21]. The results from the present study confirm and extend these findings. On the other hand, Soares et al found no significant differences in the efficacy of SNRIs and SSRIs in their study on the treatment of postmenopausal women with MDD [22]. The main reason for these inconsistencies might be the high doses of desvenlafaxine (100–200 mg/d) that did not necessarily confer a greater magnitude of efficacy but were associated with greater TEAEs. By contrast, the doses in our study, which were prescribed according to the physicians’ decision, all fell within the recommended doses, i.e., 75–225 mg/d for venlafaxine and 20–60 mg/d for fluoxetine.

There are other possible explanations for the differences in drug efficiency. First, the pharmacological profiles of the drugs could explain the clinical differences between them. Venlafaxine is an antidepressant with a mechanism of action that is believed to involve the inhibition of the uptake pumps for 5-HT and NE with inhibition of NE uptake, which is particularly relevant at high doses [23]. Fluoxetine is an antidepressant of the SSRI class [24] that mainly inhibits 5-HT. Second, estrogens decline in postmenopausal women [25], and augments the response to SSRIs in female patients with MDD [26, 27]. Animal studies support the notion that estrogens increase serotonergic activity, which could explain why postmenopausal patients have a poor response to SSRIs. Estrogen can increase 5-HT by decreasing the expression of monoamine oxidases-A (MAO-A) activity, the enzymes responsible for the degradation of 5-HT [28, 29]. Estrogens increase the activity of tryptophan hydroxylase, the rate-limiting enzyme involved in the synthesis of 5-HT, resulting in an increase in overall 5-HT availability [30, 31]. Estrogens also decrease the serotonin reuptake transporter; this transporter, located presynaptically, is very important in the elimination pathway of 5-HT from the synaptic cleft [32]. Taken together, these points could explain why menopausal depressed women were less responsive to SSRIs.

In the present study, the venlafaxine-treated group displayed a statistically significant earlier improvement of MDD symptoms compared with fluoxetine, which is consistent with a previous study [33]. Venlafaxine has an acute onset of down-regulation of β-adrenergic receptors, which might be a mechanism underlying the early onset of action [34]. It will be necessary to determine the exact mechanisms of the early improvement of depressive symptoms in menopausal women when using venlafaxine.

The present study also showed that venlafaxine significantly improved anxiety and somatization compared with fluoxetine. These findings are in line with a previous study in which venlafaxine was superior to fluoxetine in improving anxiety symptoms [33]. Similarly, a pooled analysis from five double-blind, randomized studies showed that venlafaxine is superior to fluoxetine in improving anxious symptoms [35]. The AEs and TEAEs of venlafaxine and fluoxetine were similar. Treatment discontinuation due to AEs occurred at low incidence, thus suggesting that the two drugs were well tolerated. Also, all TEAEs in the present study were mild or moderate in severity, which is again consistent with previous studies [35].

The overall health and well-being of middle-aged women have become a major public health concern around the world. According to the current life expectancy, women spend almost a third of their life being menopausal and estrogen-deficient [36]. More than 80% of the women experience physical or psychological symptoms in the years when they approach menopause, with various distress and disturbances in their lives, leading to a decreased quality of life [37]. Women are about twice as likely as men to develop depression during their lifetime, and the postmenopausal period is associated with a higher vulnerability to depression among female patients [38‐40]. Postmenopausal women are more likely to have suicidal ideation and poorer physical functioning than premenopausal and perimenopausal women [41]. Hence, it is essential to optimize pharmacologic options for the treatment of patients with postmenopausal MDD. This study suggests that women with postmenopausal major depressive disorder might benefit more from an SNRI than from an SSRI, with a more rapid and better response to treatment. The results provide some clues to optimize antidepressant pharmacotherapy for postmenopausal MDD.

This was a prospective trial, and it was finally adequately powered to verify the hypothesis; however, there are still some limitations. First, we did not measure estrogen levels at baseline. Future studies should measure estrogens, which could provide a new perspective towards understanding estrogen’s influence on antidepressants. Second, 8 weeks of antidepressant treatment were insufficient to evaluate the long-term effects, and a longer follow-up period is required. Third, we only compared two active treatments without a placebo. Fourth, Menopause-Related Symptoms were not used to evaluate hot flashes, night sweats, and other menopausal symptoms in this study. Fifth, this study did not include treatment-resistant depression (TRD) in postmenopausal depression; research in this area will be strengthened in the future. Sixth, the drop-out rate was high in this study. Finally, we did not recruit 200 patients as per the sample size calculation This non-significant finding might be due to a type II error, underlining the need for replication. Only 189 were included due to time limit and economic resources.